Effect of L-carnitine supplementation on lipid accumulation product and cardiovascular indices in women with overweight/obesity who have knee osteoarthritis: a randomized controlled trial

Table 3 Effect of L-carnitine on indices in women with knee osteoarthritis*

Indices	L-carnitine (n = 38)	Placebo (n = 38)	P^†	P^††
LAP
Baseline	88.76 (69.02 to 105.40)	100.57 (70.05 to 138.81)	0.28*	0.03
Week 12	74.70 (44.24 to 104.92)	101.69 (61.25 to 113.22)	0.05*
P	0.002**	0.05**
Mean change of LAP	− 11.05 (− 28.24 to 0.40)	− 5.82 (− 24.44 to 2.68)	0.28*
AIP
Baseline	0.09 ± 0.19	0.09 ± 0.19	0.93	0.19
Week 12	0.04 ± 0.17	0.08 ± 0.20	0.37
P	0.04	0.57
Mean change of AIP	− 0.05 ± 0.16	− 0.01 ± 0.13	0.21
AC
Baseline	2.83 ± 0.79	2.53 ± 0.83	0.11	0.67
Week 12	2.43 ± 0.60	2.23 ± 0.81	0.22
P	0.004	0.008
Mean change of AC	− 0.40 ± 0.81	− 0.30 ± 0.67	0.57
CRI-II
Baseline	2.32 ± 0.77	2.07 ± 0.73	0.15	0.11
Week 12	2.12 ± 0.47	1.85 ± 0.57	0.03
P	0.11	0.01
Mean change of CRI-II	− 0.20 ± 0.76	− 0.21 ± 0.47	0.94

Values for AIP, AC and Castelli risk index II are presented as mean ± standard deviation (SD), while for LAP are presented as median and quartile range
*P values are computed by Mann–Whitney U test
**P values are computed by Wilcoxon test
P: resulted from within each group comparison
P^†: resulted from comparing the means of each variable at the end of the study, between groups
P^††: adjusted based on education and baseline values of parameters using univariate ANCOVA
LAP: lipid accumulation product; AIP: atherogenic index of plasma; AC: atherogenic coefficient; CRI-II: Castelli risk index II

ISSN: 2520-1026